Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

Fineline Cube Mar 19, 2026
Company Deals

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

Fineline Cube Mar 19, 2026
Company Deals

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

Fineline Cube Mar 19, 2026
Company Deals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder

Fineline Cube Mar 19, 2026
Company Deals

Viva Biotech Partners with NVIDIA to Optimize AI Drug Design – Proteina Complexa Model Targets ActRIIA Mini‑Binders

Fineline Cube Mar 19, 2026
Policy / Regulatory

FDA Releases Draft Guidance on NAMs – Accelerating Shift from Animal Testing to Human‑Relevant Drug Safety Assessment

Fineline Cube Mar 19, 2026
Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Fineline Cube Mar 19, 2026
Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Fineline Cube Mar 19, 2026
Company Deals

Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech

Fineline Cube Aug 18, 2022

China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....

Company Drug R&D

Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China

Fineline Cube Aug 18, 2022

The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...

Policy / Regulatory

CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications

Fineline Cube Aug 18, 2022

The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...

Drug

ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer

Fineline Cube Aug 18, 2022

Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...

Drug

BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia

Fineline Cube Aug 18, 2022

Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...

Company Legal / IP

GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement

Fineline Cube Aug 18, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...

Company Drug

Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy

Fineline Cube Aug 18, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Digital Hospital

Baidu Health’s Precision Matching Engine Powers Public Hospitals

Fineline Cube Aug 18, 2022

China Internet giant Baidu’s one-stop health management platform Baidu Health has updated the status of...

Company

WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth

Fineline Cube Aug 18, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKEX: 2269) published its unaudited...

Company Deals

MingMed Biotech’s Hong Kong IPO Signals Push for First-in-Class Drugs

Fineline Cube Aug 18, 2022

Guangzhou-based MingMed Biotech has officially made an initial public offering (IPO) to the Hong Kong...

Company Drug

Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing

Fineline Cube Aug 18, 2022

China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...

Company Deals

Applied Protein Technology Raises Hundreds of Millions in Series B Funding

Fineline Cube Aug 17, 2022

Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision...

Company Deals Drug

SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China

Fineline Cube Aug 17, 2022

SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment

Fineline Cube Aug 17, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Deals

Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion

Fineline Cube Aug 17, 2022

Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly...

Medical Device

Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds

Fineline Cube Aug 17, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...

Company

Sihuan Pharmaceutical Restructures with Dual Organization Model

Fineline Cube Aug 17, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...

Company Deals

Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China

Fineline Cube Aug 17, 2022

China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...

Company Drug

Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention

Fineline Cube Aug 17, 2022

The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable...

Company Deals

Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies

Fineline Cube Aug 17, 2022

Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly...

Posts pagination

1 … 606 607 608 … 636

Recent updates

  • Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients
  • Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer
  • Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma
  • InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis
  • Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.